Overview
Insilico Medicine offers AI-powered drug discovery platforms like Pharma.AI, PandaOmics for target identification, and Chemistry42 for novel molecule design to pharmaceutical companies. These tools enable end-to-end preclinical development, from target prioritization to Phase 1 readiness in 30 months, with licensing available. The company supports partnerships, including global R&D collaborations like with Eli Lilly, across fibrosis, cancer, immunology, and aging-related diseases, with 31 internal programs including 7 in clinical stages.
Frequently asked questions
- What AI platforms does Insilico Medicine provide for drug discovery?
- Insilico's Pharma.AI suite includes PandaOmics for target discovery and prioritization, Chemistry42 for generative molecule design, and Nach01 for multimodal molecular tasks like property prediction and retrosynthesis.
- What are Insilico's key therapeutic areas and pipeline status?
- Focus areas include fibrosis, cancer, immunology, and aging-related diseases, with a pipeline of 31 programs across 29 targets, including 7 in clinical stages and one in Phase 2 for idiopathic pulmonary fibrosis.
- Does Insilico offer licensing, partnerships, or global collaborations?
- Yes, they provide target discovery tools for licensing, pilot automated AI-driven partnering systems, and global R&D collaborations such as with Eli Lilly for multiple therapeutic areas.